{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:43:27Z","timestamp":1790628207684,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Lincoln Memorial University"},{"name":"DeBusk College of Osteopathic Medicine"},{"name":"\u201c5\u00d71000\u201d Voluntary Contribution"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["BBA Clinical"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bbacli.2015.11.004","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T10:45:59Z","timestamp":1447497959000},"page":"25-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-9936","authenticated-orcid":false,"given":"Paul L.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cervellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbacli.2015.11.004_bb0005","first-page":"4","article-title":"Critical assessment of the status of Alzheimer's disease biomarkers","volume":"1","author":"Wood","year":"2014","journal-title":"J. Parkinson's disease & Alzheimer's disease"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2147\/CIA.S73922","article-title":"Mild cognitive impairment and its management in older people","volume":"10","author":"Eshkoor","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0015","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","article-title":"Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not \u03b2-amyloid in cognitively normal older individuals","volume":"33","author":"Wirth","year":"2013","journal-title":"J Neurosci."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0020","first-page":"1512","article-title":"Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people","volume":"70","author":"Wirth","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/alzrt103","article-title":"Lipidomics of Alzheimer's disease","volume":"4","author":"Wood","year":"2012","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0035","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1194\/jlr.P700023-JLR200","article-title":"Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia","volume":"48","author":"Goodenowe","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1503\/jpn.090059","article-title":"Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients","volume":"35","author":"Wood","year":"2010","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpba.2014.05.023","article-title":"Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry","volume":"98C","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0050","first-page":"1001","article-title":"Increased lysophosphatidylethanolamine and diacylglycerol levels in Alzheimer's disease plasma","volume":"1","author":"Wood","year":"2014","journal-title":"JSM Alzheimer's Disease and Related Dementia"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-150336","article-title":"Targeted lipidomics of frontal cortex and plasma diacylglycerols (DAG) in mild cognitive impairment (MCI) and Alzheimer's disease: validation of DAG accumulation early in the pathophysiology of Alzheimer's disease","volume":"48","author":"Wood","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(95)00931-F","article-title":"Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain","volume":"698","author":"Ginsberg","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0065","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1046\/j.1471-4159.2001.00332.x","article-title":"Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry","volume":"77","author":"Han","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0070","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","article-title":"Comparative lipidomic analysis of mouse and human brain with Alzheimer disease","volume":"287","author":"Chan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/neu.2015.18","article-title":"Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects","volume":"27","author":"Wood","year":"2015","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0080","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.neurobiolaging.2014.02.025","article-title":"The brain lipidomes of subcortical ischemic vascular dementia and mixed dementia","volume":"35","author":"Lam","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.talanta.2014.07.075","article-title":"Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease","volume":"131","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2015","journal-title":"Talanta"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio.13.346","article-title":"Lipidomics of Alzheimer's disease","volume":"6","author":"Touboul","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.irn.2015.05.008","article-title":"Lipidomics of human brain aging and Alzheimer\u2019s disease pathology","volume":"122","author":"Naud\u00ed","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0100","doi-asserted-by":"crossref","first-page":"309507","DOI":"10.1155\/2014\/309507","article-title":"Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment","volume":"2014","author":"Cervellati","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1207\/S15324826AN0902_7","article-title":"Construct validity of the Babcock story recall test","volume":"9","author":"Horner","year":"2002","journal-title":"Appl. Neuropsychol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0110","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","article-title":"Current concepts in mild cognitive impairment","volume":"58","author":"Petersen","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jpsychires.2006.02.008","article-title":"Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia","volume":"41","author":"Zuliani","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/npp.2013.167","article-title":"Mass spectrometry strategies for targeted clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology","volume":"39","author":"Wood","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0125","doi-asserted-by":"crossref","first-page":"a004614","DOI":"10.1101\/cshperspect.a004614","article-title":"Shotgun lipidomics on high resolution mass spectrometers","volume":"3","author":"Schwudke","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tibs.2006.11.004","article-title":"Diacylglycerol, when simplicity becomes complex","volume":"32","author":"Carrasco","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.conb.2004.05.006","article-title":"Divergent and convergent signaling by the diacylglycerol second messenger pathway in mammals","volume":"14","author":"Brose","year":"2004","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012538","article-title":"Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease","volume":"5","author":"Astarita","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00401-011-0836-9","article-title":"Peroxisomal alterations in Alzheimer's disease","volume":"122","author":"Kou","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0150","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.bbadis.2012.05.008","article-title":"Functions of plasmalogen lipids in health and disease","volume":"1822","author":"Braverman","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00294269","article-title":"Alzheimer's changes in non-demented and demented patients","volume":"89","author":"Jellinger","year":"1995","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbacli.2015.11.004_bb0160","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.neurobiolaging.2010.01.010","article-title":"Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study","volume":"2","author":"Kramer","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027291","article-title":"Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging","volume":"6","author":"Maarouf","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/01.wnl.0000341273.18141.64","article-title":"Factors associated with resistance to dementia despite high Alzheimer disease pathology","volume":"72","author":"Erten-Lyons","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bbacli.2015.11.004_bb0175","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11064-011-0674-0","article-title":"Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer's disease neuropathology","volume":"37","author":"Crawford","year":"2012","journal-title":"Neurochem. Res."}],"container-title":["BBA Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647415000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647415000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T14:26:15Z","timestamp":1537194375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214647415000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":35,"alternative-id":["S2214647415000999"],"URL":"https:\/\/doi.org\/10.1016\/j.bbacli.2015.11.004","relation":{},"ISSN":["2214-6474"],"issn-type":[{"value":"2214-6474","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)","name":"articletitle","label":"Article Title"},{"value":"BBA Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbacli.2015.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}